HR Execs on the Move

Nanoscope Therapeutics

www.nanostherapeutics.com

 
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Aaron Osborne
 Chief Development Officer Profile

Similar Companies

Kensey Nash Corporation

Kensey Nash Corporation is a medical device company known for product development and technology in the fields of resorbable biomaterials used in a variety of medical procedures and endovascular devices. The Company provides a range of products into

Singapore General Hospital

Singapore General Hospital (SGH) is Singapore’s flagship hospital, providing specialist care, medical training, and conducting research to bring better care for patients. SGH is a not-for-profit institution with a long tradition of providing affordable...

LeonardoMD Inc

LeonardoMD Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aquor Health Care Svc

Aquor Health Care Svc is a Woodbridge, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intrexon

Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer Sectors to create biologically-based products that improve the quality of life and the health of the planet. Through the company’s proprietary UltraVector® platform and and suite of technologies, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.DNA.com.